OUR SCIENCE

InxMed translates unmet medical need into breakthrough product. Rooted in disease biology driven translational research, we develop innovative therapies targeting essential survival mechanism of tumors. 

PIPELINE

InxMed have invented a highly differentiable portfolio of novel therapeutics against full nodes in tumor defense, expanding from cell membrane to nucleus, with modalities of small molecule, antibody and ADC. The target breadth and therapeutic modalities  enable us to pursue fundamental solutions to improved efficacy and prolong survival in patients with a variety  of cancer types.

PARTNERSHIPS

Rationalized combo is a must to win the battle against cancers.  InxMed aims to invent regimen which is highly efficacious but safer. It is only possible to achieve such goal via partnership. We actively seek  co-development and strategic business development opportunities, especially  clinical combination and licensing of inhibitors of RAS pathway and ADCs. We aim to invent revolutionary, breakthrough therapies based on deep insights of underlying disease biology.